Vertex Pharmaceuticals (VRTX) received a significant boost as Health Canada's approval of ALYFTREK marked a vital step in expanding cystic fibrosis treatment options. This approval and other successes ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $470.13, denoting a +2.54% move from the preceding trading day.

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

While most altcoins targeted rebounds, Vertex Protocol’s native coin exhibited massive bearishness, driven by the ongoing ecosystem developments. The hybrid decentralized exchange has confirmed that ...

Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 10 years ago, it would be worth $3,509.46 today based on a price of $459.81 for VRTX at the time of writing.

PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Detailed price information for Vortex Energy Corp. (VRTX-CN) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals (VRTX) announced that Health Canada has granted Marketing Authorization for ALYFTREK, a new triple combination therapy for ...

Biotech company CRISPR Therapeutics has a market cap of around $5 billion, but it has the potential to be much more valuable ...

The stock's fall snapped a three-day winning streak.